SARS-CoV-2变异株突变对单克隆抗体和抗病毒药物敏感性的影响:2022年4月至2024年10月的一项非系统性综述
该非系统性综述汇总298篇文献,评估14种SARS-CoV-2变异株对欧盟/欧洲经济区批准的单克隆抗体和抗病毒药物的敏感性。ORF1ab突变导致对奈玛特韦/利托那韦敏感性中度至高度降低;卡西瑞单抗/ imdevimab对所有奥密克戎亚系中和能力高度降低;索托维单抗对BA.2、BA.4、BQ.1.1和BA.2.86效力降低;替沙格韦单抗/西加韦单抗对BQ.1、BQ.1.1、XBB、XBB.1.5和BA.2.86中和活性高度降低。
要点
- ORF1ab突变(nsp5:H172Y、nsp5:H172Y+Q189E、nsp5:L50F+E166V、nsp5:L50F+E166A+L167V)导致对奈玛特韦/利托那韦敏感性中度(25-99倍)至高度(>100倍)降低。
- 卡西瑞单抗/imdevimab对所有奥密克戎亚系中和能力高度降低;替沙格韦单抗/西加韦单抗对BQ.1、BQ.1.1、XBB、XBB.1.5和BA.2.86中和活性高度降低。
- 索托维单抗对BA.2、BA.4、BQ.1.1和BA.2.86效力降低;瑞德西韦敏感性数据未在摘要中报告。
核心结论
- 新变异株的出现,部分具有改变的抗原特征,可能导致对单克隆抗体和/或抗病毒药物的耐药性,并逃逸自然或疫苗诱导的免疫。
- 该突变、突变组合及SARS-CoV-2变异株与单克隆抗体和抗病毒药物敏感性降低的汇总,应有助于选择适当的治疗策略和/或逐步淘汰已失去疗效的疗法。
研究设计与样本
- 非系统性综述,构建文献综述汇编来自四个数据库(PubMed、Science Direct、LitCovid和BioRxiv/MedRxiv预印本服务器)的298篇出版物。
- 纳入截至2024年10月1日欧洲药品管理局(EMA)批准的奈玛特韦/利托那韦、瑞德西韦、替沙格韦单抗/西加韦单抗、瑞丹维单抗、卡西瑞单抗/imdevimab和索托维单抗相关出版物。
主要发现
- ORF1ab中鉴定的突变nsp5:H172Y、nsp5:H172Y和Q189E、nsp5:L50F和E166V、nsp5:L50F、E166A和L167V导致对奈玛特韦/利托那韦敏感性降低,范围从中度(25-99倍)至高度(>100倍)。
- 卡西瑞单抗/imdevimab在所有奥密克戎亚系中表现出高度降低的中和能力。
- 亚系BA.1、BA.2和BA.5对瑞丹维单抗敏感性降低,而索托维单抗对BA.2、BA.4、BQ.1.1和BA.2.86显示效力降低。
- 替沙格韦单抗/西加韦单抗对BQ.1、BQ.1.1、XBB、XBB.1.5和BA.2.86亚系表现出高度降低的中和活性。
临床怎么用
- 该突变、突变组合及SARS-CoV-2变异株与单克隆抗体和抗病毒药物敏感性降低的汇总,应有助于选择适当的治疗策略和/或逐步淘汰已失去疗效的疗法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundMonoclonal antibodies (mAbs) and antiviral drugs have emerged as additional tools for treatment of COVID-19.AimWe aimed to review data on susceptibility of 14 SARS-CoV-2 variants to mAbs and antiviral drugs authorised in the European Union/European Economic Area (EU/EEA) countries.MethodsWe constructed a literature review compiling 298 publications from four databases: PubMed, Science Direct, LitCovid and BioRxiv/MedRxiv preprint servers. We included publications on nirmatrelvir and ritonavir, remdesivir and tixagevimab and cilgavimab, regdanvimab, casirivimab and imdevimab, and sotrovimab approved by the European Medicines Agency (EMA) by 1 October 2024.ResultsThe mutations identified in the open reading frame (ORF)1ab, specifically nsp5:H172Y, nsp5:H172Y and Q189E, nsp5:L50F and E166V and nsp5:L50F, E166A and L167V, led to a decrease in susceptibility to nirmatrelvir and ritonavir, ranging from moderate (25-99) to high reductions (> 100). Casirivimab and imdevimab exhibited highly reduced neutralisation capacity across all Omicron sub-lineages. Sub-lineages BA.1, BA.2 and BA.5 had decreased susceptibility to regdanvimab, while sotrovimab showed decreased efficacy for BA.2, BA.4, BQ.1.1 and BA.2.86. Tixagevimab and cilgavimab exhibited highly reduced neutralisation activity against BQ.1, BQ.1.1, XBB, XBB.1.5 and BA.2.86 sub-lineages.ConclusionsThe emergence of new variants, some with altered antigenic characteristics, may lead to resistance against mAbs and/or antiviral drugs and evasion of immunity induced naturally or by vaccination. This summary of mutations, combination of mutations and SARS-CoV-2 variants linked to reduced susceptibility to mAbs and antiviral drugs, should aid the selection of appropriate treatment strategies and/or phasing out therapies that have lost their effectiveness.
引用
- Vukovikj M, Melidou A, Nannapaneni P, et al. Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024. Euro Surveill. 2025. PMID: 40084420. doi:10.2807/1560-7917.ES.2025.30.10.2400252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。